Cargando…

Long-term complete response to gefitinib after treatment termination in a patient with recurrent post-operative EGFR-mutated lung adenocarcinoma: case report and literature review

Non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations is highly sensitive to EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, few cases of advanced NSCLC completely cured by EGFR-TKIs have been reported. We present an extremely rare case of lung adenocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Kenji, Haratake, Naoki, Takenaka, Tomoyoshi, Nagano, Taichi, Oku, Yuka, Kosai, Keisuke, Ono, Yuki, Kohno, Mikihiro, Oda, Yoshinao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798613/ https://www.ncbi.nlm.nih.gov/pubmed/35116352 http://dx.doi.org/10.21037/tcr-21-1140

Ejemplares similares

Clinical significance of the combination of preoperative SUVmax and CEA in patients with clinical stage IA lung adenocarcinoma
por: Hashinokuchi, Asato, et al.
Publicado: (2022)

Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy
por: Watanabe, Kenji, et al.
Publicado: (2023)

Surgical resection of a tuberculoma in the diaphragm: a case report
por: Hashinokuchi, Asato, et al.
Publicado: (2022)

Multiple systemic artery to pulmonary vessel fistulas (SAPVFs) completely resected by video-assisted thoracoscopic surgery: a case report
por: Matsudo, Kyoto, et al.
Publicado: (2022)

Relationship between consolidation tumor ratio and tumor‐infiltrating lymphocytes in small‐sized lung adenocarcinoma
por: Ono, Yuki, et al.
Publicado: (2022)

Conservative treatment for residual lung congestion after left upper trisegmentectomy: a case report
por: Nagano, Taichi, et al.
Publicado: (2023)

Mediastinal synovial sarcoma invading the right inferior pulmonary vein and left atrium
por: Nagano, Taichi, et al.
Publicado: (2023)

Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Impact of the pretreatment prognostic nutritional index on the survival after first‐line immunotherapy in non‐small‐cell lung cancer patients
por: Oku, Yuka, et al.
Publicado: (2023)

Clinical significance of preoperative inflammatory markers in non-small cell lung cancer patients: A multicenter retrospective study
por: Takada, Kazuki, et al.
Publicado: (2020)

Is radical local therapy effective in postoperative recurrent EGFR ‐mutated non‐small cell lung cancer?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2023)

MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma
por: Nakanishi, Takayuki, et al.
Publicado: (2023)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Achievement of Cure with Gefitinib in Advanced Lung Adenocarcinoma Harboring an Activating EGFR Mutation: A Case Report
por: Kuwata, Taiji, et al.
Publicado: (2016)

Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma
por: Kinoshita, Fumihiko, et al.
Publicado: (2023)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
por: Haratake, Naoki, et al.
Publicado: (2020)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on (18)F‐fluorodeoxyglucose positron emission tomography/computed tomography
por: Takada, Kazuki, et al.
Publicado: (2017)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Repeated treatment with gefitinib and alectinib in a patient with multiple EGFR-mutant and ALK-mutant lung adenocarcinomas: A case report
por: Yorozuya, Takafumi, et al.
Publicado: (2021)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

The significant influence of having children on the postoperative prognosis of patients with nonsmall cell lung cancer: A propensity score‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2018)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Does short-term cessation of smoking before lung resections reduce the risk of complications?
por: Takenaka, Tomoyoshi, et al.
Publicado: (2020)

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
por: Pao, William, et al.
Publicado: (2005)

Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
por: Bria, Emilio, et al.
Publicado: (2015)

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma
por: L’Hostis, Adèle, et al.
Publicado: (2023)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Stathmin is involved in the cooperative effect of Zoledronic acid and gefitinib on bone homing breast cancer cells in vitro
por: Oda, Miki, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
por: He, Peng, et al.
Publicado: (2013)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status
por: Douillard, Jean-Yves, et al.
Publicado: (2014)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
por: Britain, Colleen M., et al.
Publicado: (2018)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
por: Huang, Yanjun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nhfb4hd8coc0ms6q2o37448749